Sarcopenia - Pipeline Review, Q4 2010

Global Markets Direct, December 2010, Pages: 27

Sarcopenia - Pipeline Review, Q4 2010

Summary

Global Markets Direct’s, “Sarcopenia Pipeline Review, Q4 2010”, provides an overview of the Sarcopenia therapeutic pipeline. This report provides information on the therapeutic development for Sarcopenia , complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Sarcopenia . “Sarcopenia -Pipeline Review 2010, Q4 2010” is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- A snapshot of the global therapeutic scenario for Sarcopenia   .
- A review of the Sarcopenia    products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Sarcopenia    pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- A snapshot of the global therapeutic scenario for Sarcopenia   .
- A review of the Sarcopenia    products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Sarcopenia    pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Sarcopenia Overview
Therapeutics Development
An Overview of Pipeline Products for Sarcopenia
Sarcopenia Therapeutics under Development by Companies
Sarcopenia Therapeutics under Investigation by Universities/Institutes
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Companies Involved in Sarcopenia Therapeutics Development
GlaxoSmithKline plc
Merck & Co., Inc.
Neurotune AG
Universities/Institutes Involved in Sarcopenia Therapeutics Development
Sarcopenia Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Customers who bought this item also bought

• The World Market For Sexual Disorders, 2005-2012: Traversing New Frontiers in Sexual Chemistry
• Nausea – Pipeline Review, H1 2013
• Psychosis – Pipeline Review, H1 2013
• Musculoskeletal Disorders Therapeutics Market to 2017 - Osteoarthritis Market to Decline with Patent Expiry of Celebrex in 2014
• Ebola Viral Infections – Pipeline Review, H1 2013
• Peanut Allergy – Pipeline Review, H1 2013
• AIDS - Related Kaposi's Sarcoma – Pipeline Review, H1 2013
• Natural Killer Cell Lymphomas – Pipeline Review, H1 2013
• HIV / AIDS – Pipeline Review, H1 2013
• Drug Addiction – Pipeline Review, H1 2013